Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

PeerView Gastroenterology CME/CNE/CPE Video Podcast

Go online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine- or platinum-containing chemotherapy, while novel combinations with anti-angiogenesis agents, chemotherapy, and/or immunotherapy are showing promise in clinical trials. Furthermore, first-line therapy with an immune checkpoint inhibitor in combination with chemotherapy recently demonstrated improved outcomes over chemotherapy alone, and these data led to an FDA approval that is ushering in a new immunotherapy-based standard of care in the frontline treatment of newly diagnosed gastric and GEJ cancers. Join PeerView for an innovative, case-based activity designed to bring participants the latest data on established targeted therapies and emerging combination strategies for patients with gastric and GEJ cancers and expert guidance on incorporating treatment advances into day-to-day clinical practice. With a focus on multidisciplinary care of patients with gastric and GEJ cancers, the faculty panel will address selection and sequencing of treatment regimens along with symptom management, psychological support, nutritional considerations, and a variety of other issues that affect patients’ quality of life and outcomes. Upon completion of this accredited CE activity, participants should be better able to: Evaluate the latest clinical evidence on established targeted therapies (eg, anti-angiogenic agents) and emerging combination strategies (eg, with chemotherapy or immune checkpoint inhibitors) for patients with advanced gastric or GEJ cancer, Discuss the clinical implications of recently approved and emerging first-line treatment strategies in the settings of advanced gastric or GEJ cancer that take into consideration the potential impact of treatment selection and sequencing beyond first-line therapy, Implement a tailored approach to treatment selection and sequencing over multiple lines of therapy, based on the latest clinical evidence, current practice guidelines, and patient-, disease-, and treatment-specific factors, for patients with advanced gastric or GEJ cancer, Integrate multidisciplinary, interprofessional, and holistic care strategies that address nutritional needs, emotional and psychological concerns, treatment-related adverse events, the risk of disease progression, and other issues into the management of patients with advanced gastric or GEJ cancer.